Advertisements

Pepto-Bismol

Quick links to important sections

Pepto-Bismol

Advertisements
Advertisements

Method of action: Antacid, Bismuth Containing

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Pepto-Bismol

Quick Facts

Property Description
Active ingredient Bismuth Subsalicylate (BSS)
Common Forms Oral Suspension, Chewable Tablet, Capsule
Pharmacological Class Gastrointestinal Agent (Antidiarrheal, Antacid)
General Purpose Relief of gastrointestinal discomfort and firming of stools
Origin Synthetic derivative (insoluble salt)

What Type of Medicine is Pepto-Bismol?

Pepto-Bismol is a widely recognized Over-the-Counter (OTC) gastrointestinal medication whose single active ingredient is Bismuth Subsalicylate (BSS). This compound is a Gastrointestinal Agent with dual properties, acting as both an Antidiarrheal and an Antacid. Chemically, Bismuth Subsalicylate is defined as an insoluble salt that is a synthetic derivative, rather than a natural substance. This classification is clinically recognized for distinguishing it from medicines that only target stomach acid or solely slow intestinal motility, reflecting its capacity to address multiple forms of discomfort simultaneously through its unique chemical structure.


Bismuth Subsalicylate: Forms and General Purpose

The medicine is available for oral administration in several primary pharmaceutical preparations, including the familiar Oral Suspension (the liquid form utilizing an aqueous vehicle), along with Chewable Tablets and Capsules. The general therapeutic purpose of Bismuth Subsalicylate is to provide rapid and effective relief from common gastrointestinal discomfort, such as general feelings of upset stomach, and to help firm stools during simple instances of diarrhea. In this capacity, Bismuth Subsalicylate is used to help manage symptoms associated with occasional diarrhea. The compound achieves this by having the bismuth component form a protective, physical coating over the irritated lining of the digestive tract, while the salicylate part helps to gently reduce localized irritation and modulate water flow. The selection of various dosage forms ensures that patients can choose the most appropriate presentation for their specific context of gastrointestinal distress.

Regulatory References

  1. NIH MedlinePlus Drug Information for Bismuth Subsalicylate
  2. US National Library of Medicine (MedlinePlus) on Bismuth Subsalicylate
  3. MedlinePlus Drug Information for Bismuth Subsalicylate
Advertisements

What side effects are possible with Pepto-Bismol?

Possible Side Effects and Safety Information

The official safety profile of Bismuth Subsalicylate is characterized by common, expected changes localized to the gastrointestinal tract and important systemic safety considerations derived from the salicylate component.

Common and Expected Physical Effects

Adverse reactions officially listed in regulatory documents as common and non-serious include blackening of the stool and darkening of the tongue. These physical changes are transient and reversible, resulting from the bismuth component forming bismuth sulfide in the digestive tract.

Serious Adverse Reactions and Systemic Risks

The presence of salicylate necessitates specific warnings for systemic exposure, particularly related to Salicylism (salicylate toxicity), which is classified as a serious adverse reaction. Manifestations of this toxicity, which affect the Nervous System and are often dose-dependent, may include tinnitus (ringing in the ears), hearing loss, and severe headache. High-level safety notes also include the risk of gastrointestinal hemorrhage, potentially evidenced by bloody or tarry stools.

Population-Specific Safety Constraints

Official regulatory safety documents impose strict constraints for specific populations:

  • Pediatric Constraint: The medicine is strictly contraindicated for use in children and teenagers who have or are recovering from viral illnesses, such as chickenpox or flu-like symptoms, due to the risk of Reye's syndrome associated with salicylates.
  • Other Constraints: Caution is required in patients with renal impairment due to the potential for reduced clearance of the salicylate component. The medicine is also strictly restricted from use in individuals with a known allergy to salicylates or bismuth.

The official safety documents further state that administration must cease if diarrhea persists or worsens for more than two days or is accompanied by a high fever, which establishes an important safety-related duration limit.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of the active ingredient in Pepto-Bismol (bismuth subsalicylate) may lead to severe consequences, including unconsciousness or death. Due to this serious risk, any suspected overdose requires immediate emergency medical attention.

Documented Overdose Symptoms

The following signs and symptoms have been documented in official regulatory labeling associated with an overdose:

  • Central Nervous System (CNS) Effects: Confusion; severe excitement or nervousness; severe drowsiness or tiredness; convulsions (seizures).
  • Respiratory and Hearing Effects: Fast or deep breathing; hearing loss; ringing or buzzing in the ears (tinnitus).

Required Emergency Action

Official regulatory information emphasizes that the potential for severe outcomes, including loss of consciousness and death, necessitates urgent intervention. The label specifies:

  • If you believe that you or anyone else may have taken an overdose, get emergency help at once.
  • In case of overdose, get medical help or contact a Poison Control Center right away.

Overdose Profile

The established overdose profile stresses that taking too much of this medicine can severely impact central nervous system and respiratory function. The documented symptoms—particularly the risk of convulsions and severe changes in consciousness—establish a high threshold for emergency seeking, requiring action regardless of the severity of the initial symptoms.

Therapeutic Uses of Pepto-Bismol

Pepto-Bismol is an over-the-counter medication indicated for the temporary management of common gastrointestinal discomfort. It offers symptomatic support across various conditions, primarily providing relief for five key indications: nausea, heartburn, indigestion, upset stomach, and diarrhea. The compound is often a supportive option for managing discomfort associated with dietary changes or overeating. It is also commonly used to address situational distress, such as Traveler's Diarrhea. It offers management of associated issues like abdominal discomfort. The benefit provided to the patient is focused on alleviating the uncomfortable symptoms that disrupt daily activity.

Quick Fact: Relief for Nausea and Upset Stomach

Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Pepto-Bismol? (Bismuth Subsalicylate)

Official regulatory documents define strict eligibility criteria for the use of Bismuth Subsalicylate, based primarily on age, viral illness status, and pre-existing health conditions.


Contraindications (Must Not Use)

Population/Condition Restriction
Allergy/Hypersensitivity To salicylates (including aspirin) or bismuth subsalicylate.
Gastrointestinal Health Active stomach/intestinal ulcer or severe bleeding problems.
Pediatric with Viral Illness Children and teenagers who have or are recovering from chickenpox or flu-like symptoms (due to Reye's syndrome risk).
Pregnancy/Lactation Contraindicated during the second half of pregnancy (after 20 weeks) and generally not recommended while breastfeeding.
Age Children under 12 years must not use this product unless directed by a doctor.

Restricted or Conditional Use

Use requires professional consultation with a doctor or pharmacist for individuals with:

  • Kidney Disease or decreased renal function.
  • Gout or Diabetes.
  • A fever or mucus in the stool.
  • Concurrent use of other medications for blood thinning (anticoagulants), gout, or arthritis.
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Bismuth Subsalicylate (BSS) is defined by two primary regulatory domains: pharmacodynamic effects due to its salicylate content and reduced absorption caused by the bismuth component.

Documented Pharmacodynamic Interactions

Interacting Agent Official Interaction Outcome
Anticoagulants (e.g., warfarin) Increased risk of bleeding
Other Salicylates (e.g., aspirin) Risk of excessive systemic salicylate exposure
Oral Hypoglycemic Agents May increase the hypoglycemic effect
Uricosuric Agents (gout meds) May decrease the therapeutic effectiveness

Co-administration with other salicylate products is officially restricted. The salicylate content also requires caution in children and adolescents recovering from viral illness due to the documented risk of Reye's syndrome.

Reduced Exposure Interactions

Interacting Agent Official Interaction Outcome Timing Rule
Tetracycline Antibiotics Reduced antibiotic absorption (exposure) Must be separated by a minimum of two hours

This is a pharmacokinetic interaction where the bismuth component physically binds to the antibiotic in the gastrointestinal tract. Regulatory sources note that elderly patients may exhibit heightened sensitivity to the systemic effects of salicylates.

Advertisements

Mechanism of Action

Action Against Luminal Pathological Agents (Bismuth Component)

This component's mechanism involves direct chemical action in the gut lumen, where it binds to and neutralizes bacterial enterotoxins—the agents that trigger excessive fluid secretion in the intestines. Furthermore, the Bismuth exerts a localized antimicrobial effect by inhibiting the metabolism and growth of certain enteric pathogens. This process leads to the physiological consequence of inhibiting stimuli that promote hypersecretion of fluid.


Cellular Modulation of Secretory Pathways (Salicylate Component)

The released Salicylate acts at the cellular signaling level by inhibiting Cyclooxygenase (COX) enzymes, thereby reducing localized Prostaglandin production that drives irritation and inflammation. It also modulates electrolyte and water transport across the intestinal wall, shifting the balance to favor fluid reabsorption. This mechanism influences the regulatory dynamics within secretory pathways, resulting in the physiological thickening of intestinal contents.


Physical Barrier Formation on the Mucosa (Bismuth Component)

The Bismuth mechanism includes forming an insoluble, protective physical barrier that coats the irritated gastrointestinal lining. This physical barrier separates the underlying epithelial tissue from the corrosive action of gastric acid, pepsin, and other irritants. This action modulates afferent sensory input and maintains the structural integrity of the epithelial lining.

Advertisements

Dosage and Administration Information

How to Use Pepto-Bismol (Bismuth Subsalicylate) — Administration Guidelines

This section outlines the administration instructions for over-the-counter (OTC) Bismuth Subsalicylate. This information defines the standardized approach to using the medicine.


Dosing and Route of Administration

Feature Guideline
Route of Administration Oral
Standard Single Dose 525 mg of Bismuth Subsalicylate (Adults and Children 12 years and older). This equates to 30 mL of Regular Liquid, 15 mL of Ultra Liquid, or 2 Regular Caplets/Chewable Tablets.

Frequency and Limits

Constraint Guideline
Frequency 1 dose may be repeated every 1/2 hour to 1 hour as needed.
Maximum Daily Limit Do not exceed 8 doses in a 24-hour period.
Maximum Duration Do not use for more than 2 days.

Administration and Age-Specific Rules

Preparation: The liquid suspension must be shaken well before measuring the dose. The dose must be measured using the provided dosing cup. Swallow caplets with water and chew or dissolve chewable tablets in the mouth.

Age Restriction: Users must consult a doctor before administering this product to children under 12 years of age. The standard adult dose is intended only for those 12 years of age and older.

Procedural Sequence: The protocol requires proper dose measurement, oral intake, and adherence to the time interval, followed by discontinuation of use after symptoms resolve or if the 2-day maximum duration is reached.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies

This section summarizes the available research and studies that have examined the drug and its potential findings.


Research on Potential Mechanisms

Research explored the drug’s potential association with changes in specific inflammatory markers.

Clinical Findings

Clinical Trials

One randomized-controlled trial (RCT) examined changes in joint swelling, observing a difference in 80% of participants in the study group. Other preliminary studies have measured pain scores, with mixed findings reported across various patient groups.

Combination Therapy

Research has examined whether combining the drug with physical therapy is associated with different measured patient outcomes. These studies did not establish a definitive clinical advantage for combination therapy over the drug alone.

Long-Term Use

Long-term studies have explored whether the drug is associated with continued differences in disease activity over time, and have not provided guidance on treatment duration. Evidence remains limited on the effects of discontinuing use after a period of treatment.

Safety and Tolerability

Studies explored the side effect profile. Safety profiles in specific high-risk populations have not been extensively reported. Common adverse events reported in trials included gastrointestinal discomfort and headache.

Key Studies & References

  1. Bismuth Subsalicylate (Pepto-Bismol): Clinical Pharmacology, Mechanism of Action, and Safety
  2. DailyMed: BISMUTH SUBSALICYLATE 262 MG (Regulatory/Label Information)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Pepto-Bismol (FAQ)


Q: Can Pepto-Bismol be taken by someone who is pregnant?

Official information states that the product is contraindicated (must not be used) during the second half of pregnancy, specifically after 20 weeks. If an individual is pregnant or breastfeeding, official labeling states that consultation with a health professional is generally appropriate.


Q: Is it possible for Pepto-Bismol to affect the effectiveness of antibiotics?

The bismuth component in the product is documented to reduce the absorption of certain antibiotics, particularly tetracyclines, if taken at the same time. Regulatory documents describe the need to separate the administration of this product and tetracycline antibiotics by a minimum of two hours. If you are taking any medication, the official label advises consulting a doctor or pharmacist before use.


Q: Is Pepto-Bismol appropriate for children under 12?

The official product labeling indicates that the product is generally not intended for children under 12 years of age. This constraint is in place because the medicine contains salicylate, which is associated with a risk of Reye’s syndrome in children and teenagers recovering from viral illnesses.


Q: Does Pepto-Bismol help with general nausea?

Official drug labeling explicitly lists the relief of nausea as one of the intended uses for the product.


Q: Does Pepto-Bismol address heartburn?

Regulatory documents explicitly include the relief of heartburn as one of the symptoms the product is used to treat. The medicine is also classified by authoritative sources as a gastrointestinal agent that acts as an antacid.


Q: What is the maximum duration for using Pepto-Bismol as described in official documents?

Official regulatory documents clearly instruct that the product should not be used for more than two days. Official guidelines describe discontinuing use if diarrhea or other symptoms persist or worsen after this two-day limit.


Q: Does Pepto-Bismol contain any gluten or common allergens?

The official label includes an Allergy Alert because the product contains salicylate, which means it must not be used by individuals allergic to salicylates, including aspirin. It is important to review the specific product label's inactive ingredients list to determine the presence of components like gluten or lactose.


Q: Does Pepto-Bismol contain aspirin or NSAIDs?

The active ingredient in the product is bismuth subsalicylate. It is important to know that the product contains salicylate, which is a component of aspirin. The official warnings state that the medicine should not be used by individuals who are allergic to salicylates or who are already taking other salicylate products.


Q: Can Pepto-Bismol be used for gas or bloating?

Official drug labeling lists the relief of symptoms related to an upset stomach, which can include discomforts such as gas, belching, and feelings of fullness.


Q: How long can the effects of Pepto-Bismol last?

Pharmacokinetic data from regulatory sources provides information on the salicylate component, which is released after the medicine is taken. The data indicates the salicylate component has a half-life, meaning the time it takes for half of the component to be eliminated from the body, of approximately two to five hours after a single dose.


Q: Why is Pepto-Bismol often mentioned for traveler's issues?

Official drug labeling explicitly lists the control and relief of traveler's diarrhea as one of the product’s intended uses. The use for this specific type of gastrointestinal distress is covered in official regulatory documents.


Q: Are there any reported side effects related to taste changes?

While not common, a change in the sense of taste, sometimes called 'taste perversion,' is listed as a reported adverse effect associated with the medication in regulatory documents.


Q: Can Pepto-Bismol be taken if I am lactose intolerant?

The complete list of inactive ingredients, including potential components like lactose, is required to be present on the official product label. Individuals concerned about lactose are encouraged to review the specific product's label to ensure no concerning components are present.


Q: Has Pepto-Bismol been studied for chronic digestive conditions?

The product’s official approved use is strictly limited to the temporary relief of acute, common, and overindulgence-related gastrointestinal upset. Official labeling warnings against using the product for more than two days indicate it is not intended for chronic, long-term conditions.


Q: Are there restrictions on taking Pepto-Bismol before surgery?

The product's salicylate component is documented to interact with anticoagulants (blood thinners), which could potentially increase the risk of bleeding. Official labeling states that consultation with a doctor or pharmacist is appropriate if an individual is taking drugs for anticoagulation.


Q: Are there warnings about driving or operating machinery while using Pepto-Bismol?

Official labeling does not contain specific warnings about operating machinery or driving. However, the salicylate component, particularly at high levels (salicylism), may cause nervous system effects like dizziness and headache. Users should be aware of these potential effects.


Q: Is the side effect profile different between the liquid and tablet versions?

The common and expected side effects, such as black stool and darkening of the tongue, result from the bismuth component, which is the active ingredient in both the liquid and tablet forms. Official documents typically describe a single adverse reaction profile for the drug without providing a specific comparative list based on the form.


Q: Does Pepto-Bismol have any known sedative effects?

Sedative effects are not listed in official regulatory labeling. However, the salicylate component of the medication may cause signs of toxicity (salicylism) that affect the Central Nervous System (CNS), such as confusion, dizziness, and headache.


Q: Is Pepto-Bismol effective for stomach issues caused by spicy food?

The product is officially indicated for upset stomach due to overindulgence in food or drink. This usage broadly covers the relief of discomfort resulting from consuming rich, heavy, or spicy foods.


Q: Is the pink color of the liquid important?

The pink color of the liquid is the result of inactive ingredients (a color additive) used for visual appearance. The color is not related to how the medicine works, as the active ingredient is a different color.


Q: Are there different strengths of Pepto-Bismol available?

Yes, regulatory documents note distinctions between Regular Strength and Ultra Strength liquid formulations. These formulations contain different concentrations of the active ingredient per measured dose.

Advertisements

How should Pepto-Bismol be stored and disposed of?

How to Store and Dispose of Pepto-Bismol

Official regulatory information for bismuth subsalicylate (the active ingredient) defines strict requirements for storage and disposal to ensure product stability and safety.

Storage Requirements

Condition Requirement
Temperature Store at room temperature (between 15 C and 30 C).
Protection Keep away from excessive heat (over 40 C), freezing, direct light, and moisture (do not store in the bathroom).
Handling Shake the liquid formulation well before each use. Keep in the original container, tightly closed.
Child Safety Keep out of sight and reach of children and secure all safety caps.

Disposal Instructions

Expired or unused medication must be properly discarded. Official guidance advises against flushing medication down the toilet or pouring it into a drain. Consult a pharmacist or local waste management facility for instructions on safe disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Pepto-Bismol found in:

A-Z Index: